Pemafibrate, sold under the brand name Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARñ) agonist. It is developed and marketed by Kowa Pharmaceuticals.
In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.